0 CHECKOUT

Research Update: Renaissance Financial Holdings Outlook To Stable On Stabilized Capital And Liquidity Position; 'B+' Rating Affirmed Apr 11

  • ID: 1793664
  • April 2011
  • Standard & Poors

Abstract
We now believe that Russia-based Renaissance Capital investment banking group's capital and liquidity position has stabilized and that prospects are good for RenCap to meet its medium-term strategic objectives. We are revising our outlook to stable from negative on RenCap's holding company, Renaissance Financial Holdings Ltd. (RFHL). We are affirming the 'B+/B' ratings on RFHL. The stable outlook reflects our expectations that RenCap will generate moderately positive pretax income in 2011. On April 5, 2011, Standard & Poor's Ratings Services revised its outlook to stable from negative on Russia-based brokerage and investment banking house Renaissance Financial Holdings Ltd. and affirmed its 'B+' long-term and 'B' short-term counterparty credit ratings. The 'B+' long-term rating reflects the risky operating environment for investment...

Companies mentioned in this report are: Renaissance Financial Holdings Ltd.,Renaissance Capital Holdings Ltd.,Renaissance Securities Trading Ltd.,Commercial Bank Renaissance Capital
Action: Affirmed

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, READ MORE >

Note: Product cover images may vary from those shown

Renaissance Financial Holdings Ltd.,Renaissance Capital Holdings Ltd.,Renaissance Securities Trading Ltd.,Commercial Bank Renaissance Capital

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: This Credit Rating Report will be emailed to you.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS

Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer, Inc.